PDF(Pubmed)
Abstract：
UNASSIGNED: Mpox re-emerged worldwide with the multi-country outbreaks that occurred in May 2022, threatening the public health of human beings.
UNASSIGNED: This rapid systematic review summarized mpox reinfection cases documented. Electronic databases (PubMed, MedRxiv, and Social Science Research Network) were searched without time limitation, using the keywords \"mpox,\" \"monkeypox,\" & \"reinfection,\" \"reoccur,\" \"reoccurrence,\" \"episode,\" and \"relapse\". All laboratory-confirmed cases of mpox reinfection published in the literature were included in this study.
UNASSIGNED: A total of seven publications (nine cases) from Africa, Europe, and South America were included. All mpox reinfection cases were male, with a median age of 36; 88.89% of cases had unprotected sexual behaviors with other males before each illness episode. The average onset interval between the two episodes was about 4 months. Perianal lesions and lymphadenopathy were major symptoms in both episodes, and no differences in clinical severity were reported between the two episodes. The mean duration of the two episodes was approximately 22 days and 13 days, respectively; which the mean duration of the second episode was shorter than the first infection (t = 2.17, p = 0.0487). Sexually transmitted infections were commonly concurrent among most cases, accounting for 55.6% and 77.8% in the two episodes, respectively. Full vaccination against mpox was rare among reinfection cases.
UNASSIGNED: A second infection is possible even in a short period. Reinforcing monitoring, reducing high-risk behaviors, and heightening health education regarding mpox for high-risk populations are crucial to limit mpox spread, including persons with a history of mpox infection.
UNASSIGNED: This rapid systematic review summarized mpox reinfection cases documented. Electronic databases (PubMed, MedRxiv, and Social Science Research Network) were searched without time limitation, using the keywords \"mpox,\" \"monkeypox,\" & \"reinfection,\" \"reoccur,\" \"reoccurrence,\" \"episode,\" and \"relapse\". All laboratory-confirmed cases of mpox reinfection published in the literature were included in this study.
UNASSIGNED: A total of seven publications (nine cases) from Africa, Europe, and South America were included. All mpox reinfection cases were male, with a median age of 36; 88.89% of cases had unprotected sexual behaviors with other males before each illness episode. The average onset interval between the two episodes was about 4 months. Perianal lesions and lymphadenopathy were major symptoms in both episodes, and no differences in clinical severity were reported between the two episodes. The mean duration of the two episodes was approximately 22 days and 13 days, respectively; which the mean duration of the second episode was shorter than the first infection (t = 2.17, p = 0.0487). Sexually transmitted infections were commonly concurrent among most cases, accounting for 55.6% and 77.8% in the two episodes, respectively. Full vaccination against mpox was rare among reinfection cases.
UNASSIGNED: A second infection is possible even in a short period. Reinforcing monitoring, reducing high-risk behaviors, and heightening health education regarding mpox for high-risk populations are crucial to limit mpox spread, including persons with a history of mpox infection.
摘要：
■随着2022年5月发生的多国疫情，水痘在全球范围内重新出现，威胁着人类的公共卫生。
■这项快速系统评价总结了记录在案的水痘再感染病例。电子数据库(PubMed，MedRxiv,和社会科学研究网络)没有时间限制地进行搜索，使用关键字\"mpox，\"\"猴痘,\"&\"再感染,\"\"再次出现,\"\"重现,\"\"插曲,\"和\"复发\"。本研究包括文献中发表的所有实验室确诊的水痘再感染病例。
■来自非洲的总共七份出版物（九例），欧洲,南美也包括在内。所有痘痘再感染病例均为男性，年龄中位数为36岁；88.89%的病例在每次发病前与其他男性发生无保护的性行为。两次发作之间的平均发作间隔约为4个月。肛周病变和淋巴结病是两次发作的主要症状，两组患者的临床严重程度无差异.两次发作的平均持续时间约为22天和13天，第二次感染的平均持续时间短于第一次感染(t=2.17，p=0.0487)。性传播感染在大多数病例中通常并发，在这两集中分别占55.6%和77.8%，分别。在再感染病例中，完全接种水痘疫苗很少见。
■第二次感染即使在短时间内也是可能的。加强监测,减少高风险行为，加强对高危人群的水痘健康教育对于限制水痘传播至关重要，包括有水痘感染史的人。
■这项快速系统评价总结了记录在案的水痘再感染病例。电子数据库(PubMed，MedRxiv,和社会科学研究网络)没有时间限制地进行搜索，使用关键字\"mpox，\"\"猴痘,\"&\"再感染,\"\"再次出现,\"\"重现,\"\"插曲,\"和\"复发\"。本研究包括文献中发表的所有实验室确诊的水痘再感染病例。
■来自非洲的总共七份出版物（九例），欧洲,南美也包括在内。所有痘痘再感染病例均为男性，年龄中位数为36岁；88.89%的病例在每次发病前与其他男性发生无保护的性行为。两次发作之间的平均发作间隔约为4个月。肛周病变和淋巴结病是两次发作的主要症状，两组患者的临床严重程度无差异.两次发作的平均持续时间约为22天和13天，第二次感染的平均持续时间短于第一次感染(t=2.17，p=0.0487)。性传播感染在大多数病例中通常并发，在这两集中分别占55.6%和77.8%，分别。在再感染病例中，完全接种水痘疫苗很少见。
■第二次感染即使在短时间内也是可能的。加强监测,减少高风险行为，加强对高危人群的水痘健康教育对于限制水痘传播至关重要，包括有水痘感染史的人。
